Efficacy and safety of a low-flow veno-venous carbon dioxide removal device: results of an experimental study in adult sheep

Mechanical ventilation is an essential part of the care provided to the critically ill patients with acute respiratory failure (ARF). Despite the life-saving potential of this assistance, it has disadvantages and complications as well. It has been demonstrated that over-distension and cyclic inflation and deflation of alveoli can damage the alveolar–capillary barrier and initiate or amplify a local and systemic inflammation, so the concept of ventilator-induced lung injury (VILI) was introduced [1].

To prevent VILI, mechanical ventilation was rethought and a lung-protective strategy using lower pressures (plateau pressure <30 cmH₂O) and smaller tidal volumes (6 to 8 ml/kg of ideal body weight) is now accepted as the standard treatment in patients with ARF [2, 3]. Such an approach, however, may result in hypercapnia and acidosis (even within the context of 'permissive hypercapnia,' a pH value lower than 7.2 is not acceptable) [4]. In these cases, the possibility of partially removing carbon dioxide (CO₂) by using extra-pulmonary devices would be helpful in assisting the lung to maintain acceptable gas exchange.

During the last 3 years, arterovenous pumpless devices, first introduced in 1983, have become the most popular approach for extracorporeal CO₂ removal (ECCO₂R) [5]. This relatively simple technique, which uses the arterovenous pressure gradient to force blood through a very low-resistance heparinated circuit, has several advantages: lower anticoagulation requirements, small priming volume, little mechanical damage to blood components, and absence of recirculation. On the other hand, it does not offer direct blood flow control, it increases left-to-right shunt, and it could lead to lower-limb ischaemia due to prolonged arterial cannulation. Moreover, arterial access is not ideal for performing CO₂ removal within a 'multiorgan support' context, given that both renal replacement and sepsis therapies use veno-venous circuits. The aim of this study was to quantify CO₂ removal using an extracorporeal membrane gas exchanger placed in a veno-venous pump-driven bypass, collecting preliminary data in an animal model about the efficacy of the system, haemodynamic stability, and occurrence of adverse events.

Seven healthy adult female sheep with a mean body weight of 34 kg (range 25 to 41 kg) were used in this study. Animal care and treatment were conducted in accordance with institutional guidelines in compliance with national (Decreto Legislativo n.116, Gazzetta Ufficiale suppl 40, 18 febbraio 1992, Circolare n.8, Gazzetta Ufficiale, 14 luglio 1994) and international (EEC Council Directive 86/609, OJL358-1, December 1987; Guide for the Care and Use of Laboratory Animals, U.S. National Research Council, 1996) laws and policies. The protocol was approved by the Ethical Committee of the University of Turin, Italy. Sheep were transported to the laboratory at least two days before the experiment. Anaesthesia was induced (thiopentone 10 to 15 ml/kg) and maintained (isoflurorane 0.8% to 2% and remifentanyl 0.05 to 0.2 μg/kg per minute) during controlled mechanical ventilation (Drägerwerk AG, Lübeck, Germany) after endotracheal intubation, via an intravenous peripheral line. One gram of cephazoline was administered as infection prophylaxis. A femoral artery was cannulated for continuous monitoring of arterial pressure (Datex-Ohmeda, S/5; Datex-Ohmeda, Inc., Madison, WI, USA) and periodic blood sampling for gas analysis (IRMA^®; Cremascoli & Iris, Milan, Italy). Both jugular veins were cannulated using two 7.5-French catheters for connection with extracorporeal circuit (double lumen cannula did not allow an adequate flow with the sheep in ventral position) and a Swan Ganz catheter (7 French, 4 lumen, 110 cm; Arrow International, Inc., Reading, PA, USA) for periodic monitoring of cardiac output (employing thermodilution technique). Oesophageal temperature was monitored and normothermia (38°C ± 0.5°C) was maintained throughout the experiment. Saline, gelatine, and Ringer's lactate were provided for fluid replacement; low infusion rates of dopamine (2 to 5 μg/kg per minute) and norepinephrine (0.05 to 0.1 μg/kg per minute) were administered when needed as vasopressor support. Gastric tube and vescical catheter were introduced. After the completion of all invasive procedures, ventral position was maintained until the end of the experiment to avoid pulmonary atelectasis and facilitate extubation. Upon achievement of haemodynamic stability during deep anaesthesia, protective ventilation was started with the reduction of minute volume, titrated to reach an arterial partial pressure of carbon dioxide (PaCO₂) greater than 70 mmHg. After a period of at least 30 minutes without significant variations in PaCO₂, animals were connected to the CO₂ removal circuit (Decapsmart, Medica srl, Medolla (Modena), Italy) and treatment was started. No changes in ventilatory setting were made during the treatment. A bolus of 2,000 UI of heparin was administered intravenously, followed by an infusion titrated to maintain ACT (activated clotting time) value between 180 and 220 seconds. Blood was driven through the circuit by a roller non-occlusive pump (Figure 1). Blood flow through the circuit was 300 ml/hour, and warmed gas flow through the oxygenator (0.33 m²) (Polystan SAFE Micro Neonatal Oxygenator, Maquet, Rastatt, Germany^®) was kept constant at 8 l/minute of 100% oxygen. CO₂ removal treatment was maintained for three hours in five animals. Two sheep were planned to receive longer treatment (12 hours) to assess whether the CO₂ removal was maintained even after the very first time interval. After the completion of data collection, general anaesthesia was discontinued and the sheep were assisted until complete recovery and extubation.

Considering all seven sheep, we observed an average (SD) relative reduction in PaCO₂, with respect to the baseline, of 21.9% (7.7%) at 60 minutes, 18.4% (4.4%) at 90 minutes, and 17.3% (9.3%) at 210 minutes from starting treatment. After treatment discontinuation and without any variation in ventilatory setting, PaCO₂ returned to its baseline level (Figure 2).

As expected with a low-flow bypass, no significant effects occurred in oxygenation. Mean cardiac output and body temperature did not significantly change from t₀ to t₄, nor did extracorporeal blood flow (EBF), which was actually kept constant during the treatment. Thus, the EBF-to-cardiac output ratio was persistently approximately 5% (4.5% to 5.3%). All other parameters collected remained constant during the treatment.

The repeated measures analysis of variance of the five sheep receiving a short treatment course clearly indicates that PaCO₂ was significantly and persistently removed by the treatment and that suddenly after the treatment discontinuation it returned to its pre-treatment level (Table 2). The other parameters tested with this analysis (cardiac output and temperature) were not influenced by the treatment. The sensitivity analysis on PaCO₂ considering the first three sampling times of all seven sheep strengthened this result, given that the differences with the baseline (Figure 2) were all highly significant (p = 0.0004 at 60 minutes, p < 0.0001 at 90 minutes, and p = 0.003 at 210 minutes).

Two sheep were maintained under treatment for a longer time to appreciate the persistency of CO₂ removal. Although in these two cases we planned to continue the treatment for 12 hours, in one case we were forced to stop the experiment after 9 hours due to an electricity blackout. In this case, we missed the post-treatment sampling. Figure 3 shows the PaCO₂ levels in these two cases. The average PaCO₂ values during the treatment course for the two sheep were 56.5 mmHg (95% CI = 55.0 to 58.0) and 56.9 mmHg (95% CI = 54.4 to 59.4), whereas their respective baseline levels were 75.3 and 74.5 mmHg.

No adverse events in terms of bleeding, clotting of circuit, severe haemodynamic instability, or venous embolism were observed. All animals involved in the study survived and left the laboratory in good health within one week.

Although many pharmacologic and nonpharmacologic interventions have been developed to assist lung function during acute lung injury, none of them demonstrated a clear superiority and became the standard. Pharmacologic approaches included nitric oxide inhalation, surfactant replacement therapy, antioxidants, prostaglandins, and corticosteroids. Non-pharmacologic interventions are essentially represented by prone positioning, protective ventilation, PEEP (positive end-expiratory pressure), fluid management, and extracorporeal techniques, from extracorporeal membrane oxygenation (ECMO) to ECCO₂R. Unfortunately, no large randomised trial on the efficacy of extracorporeal lung assist is available, though different case series showed encouraging results in terms of survival rates among high-risk patients [6, 7].

ECMO is the first procedure proposed, but it has the disadvantages of an increased bleeding risk (even if reduced after the introduction of percutaneous cannulation techniques and heparin-coated circuits) and the requirement of specialised perfusionist staff, along with an experienced multidisciplinary team. Indeed, ECMO is a complex and invasive procedure that can be safely run in just a few dedicated centres with extensive research experience. At the time of the first studies in the 1970s, the idea of 'lung rest' (that is, using low tidal volume) [8] had no scientific rationale, and the modern concepts of 'baby lung' (that is, lower dimensions of the normally aerated tissue) [9], VILI, and protective ventilation did not yet exist. More recently, the original target of maintaining normal blood gas values has become performing the most possible gentle ventilation [9]. This could be done with the introduction of ECCO₂R, dissociating oxygenation (via the native lungs) from CO₂ removal (using veno-venous extracorporeal bypass) [10‐12]. Later on, the concept of 'permissive hypercapnia' consistently diminished the requirement of CO₂ removal as an indication for extracorporeal lung support [4].

Today, the new concept of 'permissive hypoxemia' has emerged [13]. In this context, hypercapnia and acidosis are no longer seen as harmful but even useful in improving tissue oxygenation by right-shifting the oxyhaemoglobin dissociation curve. Nonetheless, when hypercapnia and moderate hypoxiemia are tolerated as part of the clinical strategy, a method to reliably reduce PaCO₂ would still be very helpful in performing the most feasible lung-protective strategy.

A variety of recent studies have investigated the efficacy and safety of pumpless arterovenous devices to remove CO₂ [14‐17], which offer several advantages over ECMO: reduced bleeding risk, less time consumption, lower cost, no mechanical damage of blood components, and no need for a perfusionist staff. But these techniques also have their disadvantages, the most common being ischaemia of the lower limb after prolonged femoral arterial cannulation, increase of left-to-right shunt (thus excluding patients with cardiac failure), and no direct blood flow control.

Our study was designed to evaluate the efficacy and safety of a veno-venous CO₂ removal device in an animal model. By using an EBF of up to 5% of cardiac output, we succeeded in reducing PaCO₂ by 17% to 22% without variations in ventilatory setting. We observed a respiratory alkalosis in the bypassed blood (mean PaCO₂ post-filter, 22.5 mmHg; pH post-filter, 7.67; HCO₃^- post-filter, 26.0 mmol/l). However, due to the low flow of the bypass compared with the cardiac output, this did not translate into a systemic alkalosis (overall mean PaCO₂, 59.8 mmHg; pH, 7.31; HCO₃^-, 29.4 mmol/l). The CO₂ reduction was consistent at every scheduled time during the experiment, was maintained even in longer treatments (9 and 12 hours), and was not influenced by CO₂ production, as deep anaesthesia was maintained and no significant variations in cardiac output and body temperature were observed.

No adverse events in terms of bleeding, clotting of circuit, haemodynamic instability, or venous embolism were observed, thus showing the apparent safety of this technique in animal models. However, apart from the small sample size, one of the major limits of our study in this regard is represented by the shortness of treatments. Given that this technique in the clinical setting could be maintained for several days, the occurrence of long-term adverse events could consequently be different.

The results we obtained are very promising, and the possibility of applying this technique to real patients is nearer. This should be viewed as an important achievement because, regardless of whether the first applications confirmed our results, this procedure could become the first choice for ECCO₂R in patients with ARF, particularly in intensive care units experienced in depurative techniques. Increasingly, extracorporeal techniques have become a successful option for supporting different organs, from renal and liver functions to acid-base and fluid-balance control [18], to sepsis treatment [19]. In this context, different approaches, such as continuous veno-venous haemofiltration, coupled plasmafiltration adsorption, and CO₂ removal, can be performed simultaneously in what is called 'multiorgan support therapy' [20].

The very first step of this process can be considered completed. According to the model of pharmacological research, clinical studies looking at toxicity (phase I) and biological activity (phase II) should precede a large-scale randomised controlled trial before the technique can be introduced in the real world, but the effort seems worth it.